📊 NRXS Key Takeaways
Is Neuraxis, INC (NRXS) a Good Investment?
Neuraxis is a pre-revenue/early-stage company burning significant cash with zero topline growth despite high gross margins, indicating fundamental business model execution challenges. While the balance sheet is fortress-like with low debt and excellent liquidity providing ~5-6 year runway, the company must demonstrate meaningful revenue acceleration and operating leverage to justify continued equity investment.
Neuraxis shows elite gross margins but no revenue growth, while operating and net losses remain extreme, driving substantial cash burn. Liquidity is adequate short term and leverage is low, yet free cash flow of -$6.46M against $4.97M cash suggests a short runway and likely financing/dilution. Until revenue accelerates and operating efficiency improves materially, fundamentals remain unattractive.
Neuraxis, INC Key Strengths (NRXS)
- Exceptional balance sheet with only 0.03x debt-to-equity and $7.1M cash representing 81.6% of assets
- Outstanding liquidity with 2.89x current ratio and 2.81x quick ratio
- Healthy 86.4% gross margin indicates underlying product economics are viable if scaled
- High 84% gross margin indicating strong unit economics
- Low leverage (0.05x D/E) reducing insolvency risk
- Near-term liquidity support (current ratio ~2x, ~$5M cash)
NRXS Stock Risks: Neuraxis, INC Investment Risks
- Stagnant revenue of $1.6M with 0% YoY growth indicates market traction or adoption failures
- Operating expenses consuming 208% of gross profit, resulting in -108.3% operating margin
- Negative operating cash flow of -$1.2M annually with no path to profitability evident
- Company burning ~$1.3M in free cash flow annually despite strong cash balance
- Severely negative operating and net margins with large losses
- Flat revenue (0% YoY) undermines growth quality
- High cash burn and limited runway, likely capital raise/dilution
Key Metrics to Watch
- Revenue growth acceleration (critical - must exit 0% growth phase)
- Operating cash flow trend (must turn positive)
- Operating expense ratio relative to gross profit (must decrease from 208%)
- Quarterly revenue growth
- Operating cash burn and runway
Neuraxis, INC (NRXS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.89x current ratio provides a solid financial cushion.
NRXS Profit Margin, ROE & Profitability Analysis
NRXS vs Healthcare Sector: How Neuraxis, INC Compares
How Neuraxis, INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Neuraxis, INC Stock Overvalued? NRXS Valuation Analysis 2026
Based on fundamental analysis, Neuraxis, INC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Neuraxis, INC Balance Sheet: NRXS Debt, Cash & Liquidity
NRXS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Neuraxis, INC's revenue has grown significantly by 33% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.22 indicates the company is currently unprofitable.
NRXS Revenue Growth, EPS Growth & YoY Performance
NRXS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $895.7K | -$1.8M | $-0.18 |
| Q3 2025 | $666.6K | -$1.7M | $-0.24 |
| Q2 2025 | $611.5K | -$1.7M | $-0.22 |
| Q1 2025 | $646.6K | -$2.1M | $-0.32 |
| Q3 2024 | $477.5K | -$1.8M | $-0.25 |
| Q2 2024 | $611.5K | -$2.1M | $-0.42 |
| Q1 2024 | $646.6K | -$2.1M | $-0.32 |
| Q3 2023 | $477.5K | -$1.2M | $-1.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Neuraxis, INC Dividends, Buybacks & Capital Allocation
NRXS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Neuraxis, INC (CIK: 0001933567)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NRXS
What is the AI rating for NRXS?
Neuraxis, INC (NRXS) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NRXS's key strengths?
Claude: Exceptional balance sheet with only 0.03x debt-to-equity and $7.1M cash representing 81.6% of assets. Outstanding liquidity with 2.89x current ratio and 2.81x quick ratio. ChatGPT: High 84% gross margin indicating strong unit economics. Low leverage (0.05x D/E) reducing insolvency risk.
What are the risks of investing in NRXS?
Claude: Stagnant revenue of $1.6M with 0% YoY growth indicates market traction or adoption failures. Operating expenses consuming 208% of gross profit, resulting in -108.3% operating margin. ChatGPT: Severely negative operating and net margins with large losses. Flat revenue (0% YoY) undermines growth quality.
What is NRXS's revenue and growth?
Neuraxis, INC reported revenue of $1.6M.
Does NRXS pay dividends?
Neuraxis, INC does not currently pay dividends.
Where can I find NRXS SEC filings?
Official SEC filings for Neuraxis, INC (CIK: 0001933567) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NRXS's EPS?
Neuraxis, INC has a diluted EPS of $-0.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NRXS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Neuraxis, INC has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NRXS stock overvalued or undervalued?
Valuation metrics for NRXS: ROE of -30.6% (sector avg: 15%), net margin of -109.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NRXS's AI grade for 2026?
Our dual AI analysis gives Neuraxis, INC a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NRXS's free cash flow?
Neuraxis, INC's operating cash flow is $-1.2M, with capital expenditures of $31.2K. FCF margin is -78.4%.
How does NRXS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -109.5% (avg: 12%), ROE -30.6% (avg: 15%), current ratio 2.89 (avg: 2).